

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 July 2009 (02.07.2009)

PCT

(10) International Publication Number
WO 2009/082229 A2

(51) International Patent Classification:

A23L 1/305 (2006.01) A23J 3/34 (2006.01)
A23C 9/154 (2006.01) A23K 1/16 (2006.01)
A23C 19/09 (2006.01) A23L 1/05 (2006.01)
A23J 3/30 (2006.01)

(NL). ZIJTVELD-VAN DER WIEL, Johanna Henriëtte [NL/NL]; Nieuw Baarnstraat 39-2, NL-3743 BP Baarn (NL). VENEMA, Paul [NL/NL]; Bassecour 71, NL-6701 EC Wageningen (NL). VAN DER GROOT, Atze Jan [NL/NL]; Moreelsestraat 58, NL-6717 TR Ede (NL).

(21) International Application Number:

PCT/NL2008/050845

(74) Agent: HATZMANN, M.J.; Verenigde, Johan de Wittlaan 7, NL-2517 JR Den Haag (NL).

(22) International Filing Date:

22 December 2008 (22.12.2008)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2001123 21 December 2007 (21.12.2007) NL
08156298.5 15 May 2008 (15.05.2008) EP

(71) Applicant (for all designated States except US): FRIESLAND BRANDS B.V. [NL/NL]; Blankenstein 142, NL-7943 PE Meppel (NL).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): AKKERMANS, Cynthia [NL/NL]; Mingersberg 7, NL-3825 EH Amersfoort (NL). SCHOKKER, Erik Peter [NL/NL]; Swammerdamlaan 3, NL-6721 BJ Bennekom (NL). PAQUES, Marcel [NL/NL]; Julianaweg 20A, NL-3941 DM Doorn (NL). NIEUWENHUIJSE, Johannes Andries [NL/NL]; Laakse Laan 27, NL-7207 NA Zutphen

Published:

— without international search report and to be republished upon receipt of that report

(54) Title: COMPOSITION AND FIBRILS FROM PROTEINACEOUS MATERIALS

(57) Abstract: Described is a composition of peptides resulting from heat-induced acidic hydrolysis or enzymatic hydrolysis of a protein selected from the group consisting of β -lactoglobulin-containing whey protein preparation, glycinin-containing soy bean protein preparation, patatin, and mixtures thereof. The composition is capable of fibrillary aggregation upon subjection to acidic pH. Thus a pre-fibril composition is provided that has a variety of uses. Thus, they can be used to form fibrils that, in turn, have various structuring and water-retention uses, or they can be used as a food or non-food additive per se. A particular benefit is obtained in human or animal diet foods for weight-control, as the peptide prefibrils will not substantially affect a food's taste or mouthfeel, while fibrillary aggregation in gastric juice will increase satiation.



WO 2009/082229 A2

HK/P83107PC00

Title: Composition and fibrils from proteinaceous materials

The invention pertains to the making of fibrils from proteinaceous materials such as obtained from whey protein. In particular, the invention pertains to the making of fibrils from proteinaceous material obtained from a β -lactoglobulin, glycinin or patatin

As described in WO 2004/049819, β -lactoglobulin can be subjected to a process resulting in fibrils. The process comprises dissolving the β -lactoglobulin in aqueous hydrochloric acid, repeatedly diluting and filtering the protein solution, and subjecting the resulting solution to elevated temperature (e.g. 80°C) for an extended period of time (e.g. 10 hours). As described in WO 2004/049819, this process results in the protein being aggregated into fibrils. These fibrils can be used as an additive in a wide range of food and non-food products, wherein the fibrils can have varying different functions, such as foam stabilisation, enhancing of water-binding and/or texture in meat or meat-like products, general texturizing properties including viscosity improvement, gelling ability enhancement. In general, the fibrils have improved functional properties comprising thickening capability, gelling capability, foaming capability, and emulsifying capability. These improvements are described with reference to the same protein in the same concentration, but not subjected to the aforementioned process.

It will be apparent that for not all of the improved functional properties of the proteinaceous fibrils of WO 2004/049819, a fibrillar texture is desired *per se*. Further, in the manufacture of many of these products it will not be desired for the manufacturer, or the person combining ingredients into products, to conduct the above-described process before putting the additive into a product. In many such cases, a ready-to-use additive, available e.g. as a dry powder, were preferred over the *in situ* preparation of proteinaceous fibrils from proteins using the aforementioned process.

It would be desired, without detracting from the functional possibilities provided by the fibrils themselves, to make available similar functionalities in a process that does not require heating for an extended period of time. It would also be desired to provide an intermediate product that can be stored and shipped e.g. as a powder, and that is capable of being transformed into fibrils at a chosen point in time. A further desire in this respect is to provide an ingredient that can be rendered into powder from a relatively low viscous solution. It would further be desired to provide a process in which the two aspects of the afore-described fibrils, viz. functional properties and fibrillar nature, can be realized in separate process steps, or at least in separate parts of a process. By preference it would be desired if thus, by selecting conditions, the ultimate composition and functionality of the proteinaceous composition and the fibrils formed there from could be tailored. With the aim to meet one or more of these objectives, the invention, in one aspect, provides a peptide pre-fibril composition obtainable by the hydrolysis of a protein selected from the group consisting of β -lactoglobulin-containing whey protein preparation, glycinin-containing soy bean protein preparation, patatin, and mixtures thereof, wherein the hydrolysis is conducted under acidic conditions at elevated temperature, and is terminated when the hydrolysis has occurred in a sufficient manner so as to form the peptide building blocks for the fibrils, but not yet the fibrils themselves. This typically refers to a peptide pre-fibril composition obtainable by the hydrolysis of a protein selected from the group consisting of β -lactoglobulin-containing whey protein preparation, glycinin-containing soy bean protein preparation, patatin, and mixtures thereof, wherein the hydrolysis is conducted under at pH 0.5-4 at a temperature higher than 20°C, and wherein the pH is increased to neutral after at most 5 hours.

In another aspect, the invention pertains to a method of making a peptide pre-fibril composition, comprising providing a solution of a protein as described above in an aqueous acidic solvent (i.e. to subject the protein to hydrolysis conditions), heating the solution under fibril formation inhibiting conditions, and terminating the hydrolysis conditions (e.g. by increasing pH to neutral). In yet another aspect, the invention provides a variety of uses of the peptide pre-fibril compositions, including uses in which the pre-fibril composition is turned into fibrils in an end-product – that can then be used as described in WO 2004/049819, and uses in which the pre-fibril composition *per se* is contained in end product, e.g. with the aim of forming fibrils (fibrillary aggregation) upon use or consumption of the end-product. In a particular embodiment of the latter aspect of the invention, the pre-fibril composition is used in a diet food for human or animal body weight control.

As to the conditions mentioned, the elevated temperature generally means a temperature above 20°C, preferably of from 35 °C to 140 °C, and more preferably of from 80 °C to 120 °C. The acidic conditions can refer to any acid pH, but preferably a relatively strongly acidic pH, of from 0.5 to 4, more preferably of from 0.5 to 3, and most preferably of from 1 to 2. A higher temperature, above 80°C and more preferably above 100°C, is particularly preferred in view of the possibility to separate hydrolysis from fibril formation, as a higher temperature will lead to an increased rate of hydrolysis.

A further reference on protein fibrils obtained by the low pH hydrolysis of β -lactoglobulin is Cynthia Akkermans et al., FOBI (2006) 1:144-150. Herein an experiment is described in which *inter alia* the influence of shear on fibril formation is studied. It is shown that simple shear can accelerate fibril formation. In a reference experiment, initially without shear, the hydrolysis conditions are maintained under a shear flow of 200 s⁻¹ for sufficiently long lag times so as to allow the fibril formation to occur. As in WO 2004/049819, the fibrils are disclosed to be made up of protein aggregates.

Without wishing to be bound by theory, the present inventors believe that, other than suggested in the art, the so-called β -lactoglobulin fibrils, are not in fact made up of intact β -lactoglobulin protein molecules as a building block, but are made of peptide components derived from the β -lactoglobulin. This novel insight into the nature of the aforementioned proteinaceous fibrils opens up the wide range of useful possibilities now proffered by the invention. Similarly, it was found that fibrils of soy bean protein and potato protein are made up of peptides.

Particularly, by virtue of the formation of peptides, an intermediate step can be defined in the aforementioned process, viz. a step in which the hydrolysis has occurred in a sufficient manner so as to form the peptide building blocks for the fibrils, but not yet the fibrils themselves. This is referred to as a “pre-fibril composition.”

The pre-fibril composition can be characterized as obtainable in an acid hydrolysis process under conditions allowing peptide formation, or resulting in peptide formation at a relatively high rate, with fibril formation absent or at a relatively low rate. If, e.g. the process as described in WO 2004/049819 is followed, the pre-fibrils are formed if the step in which the protein is allowed to stand in a solution at low pH and high temperature, is terminated at an early point in time. The process time should be sufficiently long to allow hydrolysis in the acid environment to take place. Although within a few minutes some hydrolysis will have taken place in part, this preferably means a process time of at least 15 minutes, and more preferably at least 30 minutes. The process time should be short enough to avoid too high an extent of stable fibril formation. Although even within 15 minutes fibril formation might occur, these fibrils will not be stable. In fact, for a period of up to 5 hours fibrils will be formed, but these will disintegrate upon increasing pH to neutral. Preferably, the hydrolyzed protein is allowed to stand for a period of time of 2,5 hours or less, more preferably 1,5 hour or less. Most preferably, a period of 30-60 minutes is taken to obtain sufficient peptide formation without

undue formation of stable fibrils. Similarly, the temperature can be adapted. It will be apparent to the skilled person that a lower temperature will generally require a longer standing time for adequate hydrolysis, and will generally allow a longer standing time until fibril formation occurs.

Besides tuning time and temperature, pH can also be tuned. A lower pH will lead to a higher rate of hydrolysis, which aids in obtaining a process in which hydrolysis can occur separately from fibril formation.

It will be understood, with reference to the specific limits for pH, temperature and time by which the pre-fibrils of the invention are obtainable, in a method of making pre-fibrils conditions can be chosen that vary within, or outside of the specific

In addition to, or in lieu of, the aforementioned process of simply allowing the protein to stand under acidic hydrolysis conditions, the object of forming peptides without forming fibrils can be realized with the aid of further measures so as to provide fibril inhibiting conditions (i.e. conditions under which fibril formation is relatively slow, is retarded or is avoided, or conditions under which fibril formation, if occurring, is at least partially reversed). These measures include, but are not limited to, any one or more of the following:

- avoidance of shear forces (e.g. no stirring), with timely increase of pH to neutral;
- a low concentration of protein (preferably below 2 wt.% and more preferably below 1 wt.%);
- the addition of molecules exhibiting a chaotropic effect, i.e. molecules that will tend to counteract the formation of hydrogen bonds and hydrophobic interactions (e.g. urea, guanidine chloride); as a result the peptides will have a lower tendency to interact as close as necessary to allow bonds to form (as hydrogen bridges and hydrophobic interactions are believed to be the initial force for fibril formation);

- the addition of compounds that serve as inhibitors either by breaking a fibril-like conformation, or reversing fibrilogenesis. The first group is called mini-chaperones, also termed β -sheet breakers, which are peptides that bind to the sequence of the protein region responsible for self association. The second group is composed of small molecules, which are found to be able to interrupt fibril formation. Thus, often peptides or proteins are used as β -sheet blockers. Other potential food-grade β -sheet blockers include vitamin A, β -carotene and coenzyme Q10, oleic acid, and cholesterol.

The invention can be realised on the basis of β -lactoglobulin-containing whey protein preparations, i.e. a composition comprising whey protein, with the whey protein comprising β -lactoglobulin. Whey proteins can be described as those milk proteins that remain after curdling of milk, i.e. precipitation of casein, generally upon the addition of rennet to cheese milk. The term "whey protein" is sometimes used to indicate the entire protein composition of whey, but usually indicates any protein or combination of proteins present in whey. The invention pertains to any and all whey protein compositions comprising β -lactoglobulin, which is one of the main whey proteins. Preferably the β -lactoglobulin-containing whey protein preparation is whey protein isolate, comprising a substantial fraction (preferably, based on total proteinaceous material, at least 50% and more preferably at least 80%) of β -lactoglobulin, and most preferably it is β -lactoglobulin itself.

The invention can also be realized on the basis of glycinin (soy bean protein) or patatin (protein originating from members of the *Solanaceae* plant family, such as potato protein).

The pre-fibril composition may comprise a wide range of peptide fragments of various molecular weights, generally between 1,000 and 10,000 Da and preferably consists of peptide fragments having molecular weights between 2,000 and 8,000 Da. With respect to whey protein fibrils it is preferred

that the pre-fibril composition comprises, as the dominant fragment, i.e. the fragment that of all fragments is present most, defined by amino acids nos. 12 to 32 (f₁₂₋₃₃) of from β -lactoglobulin, i.e. IQKVAGTWYSLAMAASDISLL. This fragment can be present, as such, as part of larger fragments, or both.

Preferably the following peptides:

f₁₂₋₃₂ IQKVAGTWYSLAMAASDISLL

f₁₂₋₃₃ IQKVAGTWYSLAMAASDISLLD

f₁₁₋₃₂ DIQKVAGTWYSLAMAASDISLL

f₁₁₋₃₃ DIQKVAGTWYSLAMAASDISLLD

f₁₋₃₂: LVTQTMKGLDIQKVAGTWYSLAMAASDISLL

f₁₋₃₃: LVTQTMKGLDIQKVAGTWYSLAMAASDISLLD

f₁₋₂₇ LVTQTMKGLDIQKVAGTWYSLAMAAS

f₁₋₂₈ LVTQTMKGLDIQKVAGTWYSLAMAASD

f₁₂₋₆₄ IQKVAGTWYSLAMAASDISLLDAQSAPLRVYVEELKPT

PEGDLEILLQKWEND

f₁₁₋₆₃ DIQKVAGTWYSLAMAASDISLLDAQSAPLRVYVEELKPT

PEGDLEILLQKWEN

f₁₁₋₆₄ DIQKVAGTWYSLAMAASDISLLDAQSAPLRVYVEELKPT

PEGDLEILLQKWEND

The fragment is preferably present, as defined hereinbefore, to the extent of more than 40% of all peptides present

The peptide composition preferably further comprises one or more of the following peptides:

f₁₋₅₂: LVTQTMKGLDIQKVAGTWYSLAMAASDISLLDAQSAP

LRVYVEELKPTPEG

f₁₋₅₃: LVTQTMKGLDIQKVAGTWYSLAMAASDISLLDAQSAP

LRVYVEELKPTPEGD

f₁₃₈₋₁₆₂ KALKALPMHIRLSFNPTQLEEQCHI

f₉₉₋₁₂₈ YKKYLLFCMENSAEPEQSLACQCCLVRTPEV

f₉₉₋₁₂₉ YKKYLLFCMENSAEPEQSLACQCCLVRTPEVD

f₉₈₋₁₂₈ DYKKYLLFCMENSAEPEQSLACQCCLVRTPEV

f₉₇₋₁₂₈ TDYKKYLLFCMENSAEPEQSLACQCCLVRTPEV

This typically refers to compositions as obtainable by the aforementioned process of acidic hydrolysis. Other preferred characteristics of the prefibril peptide composition so obtainable, is that the majority of the peptide fragments result from cleavage of the peptide bonds before or after aspartic acid. The pre-fibril peptide composition is further characterized, preferably, by comprising the more hydrophobic peptides obtainable from hydrolysis of the β -lactoglobulin-containing protein preparation, by a low charge at pH 2, and by the absence of proline.

It is further envisaged to enrich the peptide composition (e.g. by fractionation) in respect of the aforementioned peptides, and preferably in respect of f₁₂₋₃₃.

Similarly, preferred fibril-forming peptide fragments on the basis of glycinin and patatin are based on the following:

Glycinin G1

Accession number: P04776

f₄₂₋₁₂₈

DNRIESEGGLIETWNPNNKPFQCAGVALSRCTLNRNALRRPSYTNGP
QEIYIQQGKGIFGMIYPGCPSTFEPPQQPQQRGQSSRPQD

f₄₂₋₁₂₇

DNRIESEGGLIETWNPNNKPFQCAGVALSRCTLNRNALRRPSYTNGP
QEIYIQQGKGIFGMIYPGCPSTFEPPQQPQQRGQSSRPQ

f₄₃₋₁₂₈

NRIESEGGLIETWNPNNKPFQCAGVALSRCTLNRNALRRPSYTNGPQ
EIIYIQQGKGIFGMIYPGCPSTFEPPQQPQQRGQSSRPQD

f₄₃₋₁₂₇

NRIESEGLIETWNPNNKPFQCAGVALSRCTLNRNALRRPSYTNGPQ
EIIYQQGKGIFGMIYPGCPSTFEEPQQPQQRGQSSRPQ

f₁₂₈₋₁₄₀ DRHQKIYNFREGDf₁₂₈₋₁₃₉ DRHQKIYNFREGf₁₂₉₋₁₄₀ RHQKIYNFREGDf₁₂₉₋₁₃₉ RHQKIYNFREGf₁₄₀₋₁₅₇ DLIAVPTGVAWWMYNNEDf₁₄₀₋₁₅₆ DLIAVPTGVAWWMYNNNEf₁₄₁₋₁₅₇ LIAVPTGVAWWMYNNEDf₁₄₁₋₁₅₆ LIAVPTGVAWWMYNNNEf₁₅₇₋₁₆₇ DTPVVAVSIIDf₁₅₇₋₁₆₆ DTPVVAVSIIf₁₅₈₋₁₆₇ TPVVAVSIIDf₁₅₈₋₁₆₆ TPVVAVSIIf₁₇₆₋₂₃₆

DQMPRRFYLAGNQQEQEFLKYQQEQGGHQSQKKGKHQQEEENEGGSIL
LSGFTLEFLEHAFSVD

f₁₇₆₋₂₃₅

DQMPRRFYLAGNQQEQEFLKYQQEQGGHQSQKKGKHQQEEENEGGSIL
LSGFTLEFLEHAFSV

f₁₇₇₋₂₃₆

QMPRRFYLAGNQQEQEFLKYQQEQGGHQSQKKGKHQQEEENEGGSIL
SGFTLEFLEHAFSVD

f₁₇₇₋₂₃₅

QMPRRFYLAGNQQEQEFLKYQQEQGGHQSQKKGKHQQEEENEGGSIL
SGFTLEFLEHAFSV

f₂₅₁₋₂₇₀ DKGAIIVTKGGLSVIKPPTDf₂₅₁₋₂₆₉ DKGAIIVTKGGLSVIKPPTf₂₅₂₋₂₇₀ KGAIIVTKGGLSVIKPPTD

f₂₅₂₋₂₆₉ KGAIVTVKGGLSVIKPPT
 f₃₁₃₋₃₃₂ DETICTMRLRHNIGQTSSPD
 f₃₁₃₋₃₃₁ DETICTMRLRHNIGQTSSP
 f₃₁₄₋₃₃₂ ETICTMRLRHNIGQTSSPD
 f₃₁₄₋₃₃₁ ETICTMRLRHNIGQTSSP
 f₃₃₂₋₃₄₈ DIYNPQAGSVTTATSLD
 f₃₃₂₋₃₄₇ DIYNPQAGSVTTATSL
 f₃₃₃₋₃₄₈ IYNPQAGSVTTATSLD
 f₃₃₃₋₃₄₇ IYNPQAGSVTTATSL
 f₃₄₈₋₄₀₃

DFPALSWLRLSAEFGSLRKNAMFVPHYNLNANSIIYALNGRALIQVV
 NCNGERVFD

f₃₄₈₋₄₀₂

DFPALSWLRLSAEFGSLRKNAMFVPHYNLNANSIIYALNGRALIQVV
 NCNGERVF

f₃₄₉₋₄₀₃

FPALSWLRLSAEFGSLRKNAMFVPHYNLNANSIIYALNGRALIQVV
 CNGERVFD

f₃₄₉₋₄₀₂

FPALSWLRLSAEFGSLRKNAMFVPHYNLNANSIIYALNGRALIQVV
 CNGERVF

f₄₀₃₋₄₂₇ DGELQEGRVLIVPQNFVVAARSQSD
 f₄₀₃₋₄₂₆ DGELQEGRVLIVPQNFVVAARSQS
 f₄₀₄₋₄₂₇ GELQEGRVLIVPQNFVVAARSQSD
 f₄₀₄₋₄₂₆ GELQEGRVLIVPQNFVVAARSQS
 f₄₂₇₋₄₃₈ DNFYVSFKTND
 f₄₂₇₋₄₃₇ DNFYVSFKTN
 f₄₂₈₋₄₃₈ NFEYVSFKTND
 f₄₂₈₋₄₃₇ NFEYVSFKTN

f₄₃₈₋₄₉₀

DTPMIGTLAGANSLLNALPEEVIQHTFNLKSQQARQIKNNNPFKFLV
PPQESQ

f₄₃₉₋₄₉₀

TPMIGTLAGANSLLNALPEEVIQHTFNLKSQQARQIKNNNPFKFLVP
PQESQ

Glycinin G5

Accession number: P04347

f₄₄₋₁₃₃

DHRVESEGGLIETWNSQHPELQCAGVTVSKRTLNRNGSHLPSYLPY
PQMIIVVQGKGAIGFAFPGCPETFEKPQQQSSRRGSRSSQQQLQD

f₄₄₋₁₃₂

DHRVESEGGLIETWNSQHPELQCAGVTVSKRTLNRNGSHLPSYLPY
PQMIIVVQGKGAIGFAFPGCPETFEKPQQQSSRRGSRSSQQQLQ

f₄₅₋₁₃₃

HRVESEGGLIETWNSQHPELQCAGVTVSKRTLNRNGSHLPSYLPYP
QMIIVVQGKGAIGFAFPGCPETFEKPQQQSSRRGSRSSQQQLQD

f₄₅₋₁₃₂

HRVESEGGLIETWNSQHPELQCAGVTVSKRTLNRNGSHLPSYLPYP
QMIIVVQGKGAIGFAFPGCPETFEKPQQQSSRRGSRSSQQQLQ

f₁₃₃₋₁₄₅ DSHQKIRHFNEGDf₁₃₃₋₁₄₄ DSHQKIRHFNEGf₁₃₄₋₁₄₅ SHQKIRHFNEGDf₁₃₄₋₁₄₄ SHQKIRHFNEGf₁₄₅₋₁₆₂ DVLVIPLGVPYWTYNTGDf₁₄₅₋₁₆₁ DVLVIPLGVPYWTYNTGf₁₄₆₋₁₆₂ VLVIPLGVPYWTYNTGD

f₁₄₆₋₁₆₁ VLVIPLGVPYWTYNTG
 f₁₆₂₋₁₇₂ DEPVVAISPLD
 f₁₆₂₋₁₇₁ DEPVVAISPL
 f₁₆₃₋₁₇₂ EPVVAISPLD
 f₁₆₃₋₁₇₁ EPVVAISPL
 f₁₈₁₋₁₉₄ DQNPRVFYLAGNPD
 f₁₈₁₋₁₉₃ DQNPRVFYLAGNP
 f₁₈₂₋₁₉₄ QNPRVFYLAGNPD
 f₁₈₂₋₁₉₃ QNPRVFYLAGNP
 f₂₅₆₋₂₈₀ DERKQIVTVEGGLSVISPKWQEQED
 f₂₅₆₋₂₇₉ DERKQIVTVEGGLSVISPKWQEQE
 f₂₅₇₋₂₈₀ ERKQIVTVEGGLSVISPKWQEQED
 f₂₅₇₋₂₇₉ ERKQIVTVEGGLSVISPKWQEQE
 f₃₄₅₋₃₆₆ GVEENICTMKLHENIARPSRAD
 f₃₄₅₋₃₆₅ GVEENICTMKLHENIARPSRA
 f₃₆₆₋₄₀₇ DFYNPKAGRISTLNSLTLPALRQFGLSAQYVVLYRNGIYSPD
 f₃₆₆₋₄₀₆ DFYNPKAGRISTLNSLTLPALRQFGLSAQYVVLYRNGIYSP
 f₃₆₇₋₄₀₇ FYNPKAGRISTLNSLTLPALRQFGLSAQYVVLYRNGIYSPD
 f₃₆₇₋₄₀₆ FYNPKAGRISTLNSLTLPALRQFGLSAQYVVLYRNGIYSP
 f₄₀₇₋₄₃₆ DWNLNANSVTMTRGKGRVRVNCQGNVFD
 f₄₀₇₋₄₃₅ DWNLNANSVTMTRGKGRVRVNCQGNVDF
 f₄₀₈₋₄₃₆ WNLNANSVTMTRGKGRVRVNCQGNVFD
 f₄₀₈₋₄₃₅ WNLNANSVTMTRGKGRVRVNCQGNVDF
 f₄₃₆₋₄₈₀
 DGELRRGQLLVVPQNPAVAEQGGEQGLEYVVFKTHHNAVSSYIKD
 f₄₃₆₋₄₇₉
 DGELRRGQLLVVPQNPAVAEQGGEQGLEYVVFKTHHNAVSSYIK
 f₄₃₇₋₄₈₀
 GELRRGQLLVVPQNPAVAEQGGEQGLEYVVFKTHHNAVSSYIKD

f 437-479

GELRRGQLLVVPQNPAVAEQGGEGGLEYYVFKTHHNAVSSYIK

f 480-516

DVFRVIPSEVLSNSYNLGQSQVRQLKYQGNSGPLVNP

f 481-516

VFRVIPSEVLSNSYNLGQSQVRQLKYQGNSGPLVNP

Patatin

Accession number: CAA25592

f 23-35

DTLGEMVTVLSID

f 23-34

DTLGEMVTVLSI

f 24-35

TLGEMVTVLSID

f 24-34

TLGEMVTVLSI

f 71-101

DVIGGTSTGGLLTAMITTPNENNRPFAAAKD

f 71-100

DVIGGTSTGGLLTAMITTPNENNRPFAAAK

f 72-101

VIGGTSTGGLLTAMITTPNENNRPFAAAKD

f 72-100

VIGGTSTGGLLTAMITTPNENNRPFAAAK

f 140-156

DTRVHQALTEVAISSFD

f 140-155

DTRVHQALTEVAISSF

f 141-156

TRVHQALTEVAISSFD

f 141-155

TRVHQALTEVAISSF

f 156-182

DIKTNKPVIFTKSNLAKSPELDAKMYD

f 156-181

DIKTNKPVIFTKSNLAKSPELDAKMY

f 157-182

IKTNKPVIFTKSNLAKSPELDAKMYD

f 157-181

IKTNKPVIFTKSNLAKSPELDAKMY

f 182-207

DICYSTAAPTYFPPHYFVTHTSNGD

f 182-206

DICYSTAAPTYFPPHYFVTHTSNG

f 183-207

ICYSTAAPTYFPPHYFVTHTSNGD

f 183-206

ICYSTAAPTYFPPHYFVTHTSNG

f 207-215

DKYEFNLVD

f 207-214

DKYEFNLV

f ₂₃₋₃₅	DTLGEMVTVLSID
f ₂₃₋₃₄	DTLGEMVTVLSI
f ₂₄₋₃₅	TLGEMVTVLSID
f ₂₄₋₃₄	TLGEMVTVLSI
f ₇₁₋₁₀₁	DVIGGTSTGGLLTAMITTPNENNRPFAAAKD
f ₇₁₋₁₀₀	DVIGGTSTGGLLTAMITTPNENNRPFAAAK
f ₇₂₋₁₀₁	VIGGTSTGGLLTAMITTPNENNRPFAAAKD
f ₇₂₋₁₀₀	VIGGTSTGGLLTAMITTPNENNRPFAAAK
f ₁₄₀₋₁₅₆	DTRVHQALTEVAISSFD
f ₁₄₀₋₁₅₅	DTRVHQALTEVAISSF
f ₁₄₁₋₁₅₆	TRVHQALTEVAISSFD
f ₁₄₁₋₁₅₅	TRVHQALTEVAISSF00
f ₁₅₆₋₁₈₂	DIKTNKPVIFTKSNLAKSPELDAKMYD
f ₁₅₆₋₁₈₁	DIKTNKPVIFTKSNLAKSPELDAKMY
f ₁₅₇₋₁₈₂	IKTNKPVIFTKSNLAKSPELDAKMYD
f ₁₅₇₋₁₈₁	IKTNKPVIFTKSNLAKSPELDAKMY
f ₁₈₂₋₂₀₇	DICYSTAAPTYFPPHYFVTHTSNGD
f ₁₈₂₋₂₀₆	DICYSTAAPTYFPPHYFVTHTSNG
f ₁₈₃₋₂₀₇	ICYSTAAPTYFPPHYFVTHTSNGD
f ₁₈₃₋₂₀₆	ICYSTAAPTYFPPHYFVTHTSNG
f ₂₀₇₋₂₁₅	DKYEFNLVD
f ₂₀₇₋₂₁₄	DKYEFNLV
f ₂₀₈₋₂₁₅	KYEFNLVD
f ₂₀₈₋₂₁₄	KYEFNLV
f ₂₃₉₋₂₆₇	DPKFASIKSLNYKQMLLLSLGTGTNSEFD
f ₂₃₉₋₂₆₆	DPKFASIKSLNYKQMLLLSLGTGTNSEF
f ₂₄₀₋₂₆₇	PKFASIKSLNYKQMLLLSLGTGTNSEFD
f ₂₄₀₋₂₆₆	PKFASIKSLNYKQMLLLSLGTGTNSEF
f ₃₀₀₋₃₃₃	DYYLSTVVFQARHSQNNYL RVQENALTGTTTEMDD
f ₃₀₀₋₃₃₂	DYYLSTVVFQARHSQNNYL RVQENALTGTTTEM D

f ₃₀₀₋₃₃₁	DYYLSTVVFQARHSQNNYL RVQENALTGTTTEM
f ₃₀₁₋₃₃₃	YYLSTVVFQARHSQNNYL RVQENALTGTTTEMDD
f ₃₀₁₋₃₃₂	YYLSTVVFQARHSQNNYL RVQENALTGTTTEMDD
f ₃₀₁₋₃₃₁	YYLSTVVFQARHSQNNYL RVQENALTGTTTEM

Based on the novel insight into the occurrence of peptides as the building blocks of the β -lactoglobulin proteinaceous fibrils, the present invention also provides an advantageous alternative method to acidic hydrolysis, viz. enzymatic hydrolysis of the β -lactoglobulin-containing whey protein preparation (or, analogously, of glycinin or patatin preparations). Thus, the advantages of enzymatic hydrolysis, such as producing the prefibril composition at neutral pH (i.e. no need for acidification and neutralization); avoidance of fibril formation at neutral pH; less unwanted side-reaction that occur at low pH) or relatively fast hydrolysis (i.e. no need for heat treatment for several hours, and unwanted reaction associated with this long heat treatment) have become available to the process of making β -lactoglobulin proteinaceous fibrils. The enzymatic hydrolysis provides a relatively great freedom to choose, by selecting the enzymes and conditions, where to achieve protein cleavage. This is preferably done so as to have a result comparable with that of acidic hydrolysis, e.g. by the enzyme AspN endoproteinase which cleaves the peptide bonds N-terminal to aspartic acid residues and other enzymes exerting a comparable action such as gramzyme B (ex Abnova Corp), V8 protease (protease from staphylococcus aureus strain V8; ex Takara Bio Inc.) and glutamyl endopeptidase.

In yet another embodiment, the pre-fibril peptide composition can also be formed by peptide synthesis. Preferably the peptides synthesized are relatively hydrophobic and, more preferably are peptides capable of undergoing β -sheet interaction. Peptide synthesis can be executed chemically in known manners, particularly using solid-phase peptide synthesis methods as are well known to the skilled person. Particularly for relatively long

peptides, such as a the peptides indicated above, it is preferred to perform the synthesis thereof by means of microbiological methods. Suitable microorganisms the genome of which encodes for the appropriate peptides, and which thus can be employed to form these peptides, are known to the skilled person. Particularly, microorganisms are to be selected that satisfy the following requirements:

- being food grade microorganisms
- their genome encoding for peptides consisting of 10 to 60 amino acids, and preferably 15 to 25 amino acids;
- the encoded peptides start and/or end with aspartic acid;
- the encoded peptides preferably consist of a (at neutral pH) uncharged amino acids;
- the encoded peptides are capable of folding into a beta-sheet conformation;

Suitable microorganisms include: BACILLUS_WEIHENSTEPHANENSIS, BIFIDOBACTERIUM_ADOLESCENTIS, BIFIDOBACTERIUM_LONGUM, BIFIDOBACTERIUM_LONGUM, BREVIBACTERIUM_LINENS, LACTOBACILLUS_ACIDOPHILUS, LACTOBACILLUS_BREVIS, LACTOBACILLUS_CASEI, LACTOBACILLUS_DELBRUECKII_SUBSP_BULGARICUS, LACTOBACILLUS_GASSERI, LACTOBACILLUS_JOHNSONII, LACTOBACILLUS_PLANTARUM, LACTOBACILLUS_REUTERI, LACTOBACILLUS_SAKEL, LACTOBACILLUS_SALIVARIUS, LACTOCOCCUS_LACTIS_CREMORIS, LACTOCOCCUS_LACTIS_LACTIS, LEUCONOSTOC_MESENTEROIDES, OENOCOCCUS_OENI, PEDIOCOCCUS_PENTOSACEUS, STREPTOCOCCUS_THERMOPHILUS.

The pre-fibril composition as formed by enzymatic hydrolysis, by chemical peptide synthesis, or by microbiological peptide formation, can be set to form fibrils upon acidification. This preferably is done to an extent comparable with the pH resulting from the aforementioned acidic hydrolysis,

i.e. the enzymatically hydrolysed β -lactoglobulin pre-fibril composition is preferably subjected to contact with a liquid at pH 0.5 to 4, and more preferably a pH of 0.5 to 3, and most preferably of from 1 to 2, thus resulting in appropriate charging of the peptide composition. The rate of fibril formation may be increased by subjecting the mixture to shear or ultrasonic treatment. One of the advantages of this route is a shorter duration of the low pH heat treatment.

The fibrils formed according to the present invention preferably have an aspect ratio of greater than 5, i.e. defining the longest dimension of the fibril as its length, this length is at least 5 times larger than the diameter or width of the fibril. Preferably the length is of from 10 nm to 1 mm, and the diameter is of from 2 to 10 nm. More preferably the aspect ratio is greater than 50. The invention provides the advantageous possibility to tailor the aspect ratio by steering the peptide composition towards the presence of peptides that facilitate the formation of fibrils (which will generally lead to a higher aspect ratio) or the presence of peptides that inhibit fibril formation, such as the aforementioned β -sheet blockers, which will generally lead to a lower aspect ratio.

The pre-fibril composition of the invention is suitable for a variety of uses. This includes uses of the pre-fibril composition itself as an additive in food and non-food products, e.g. as a structuring agent, and particularly as a texturizing agent, i.e. for viscosity or gelation. It also includes the use of the pre-fibril composition to make fibrils which then can be used *int. al.* in the same manner as described in WO 2004/049819. In addition, the invention opens up the possibility to end up with fibrils as described before, but then formed *in situ* and/or at a chosen point in time. Thus, the peptide pre-fibril composition can *int.al.* be used to stabilize an emulsion or a foam. Upon adsorption at the appropriate interface (i.e. water/oil in an emulsion or water/air in a foam), the peptide pre-fibril composition is capable of fibrillary aggregation at these interfaces, which results in a robust boundary layer, and

hence a highly stable emulsion or foam (as a result of a decreased disproportioning of the foam). Another use in which the peptide pre-fibril composition of the invention is used for its ability to form fibrils, is by adding the composition as an ingredient to an acidic liquid (e.g. fruit juice or yoghurt drink), to result in fibrillary aggregation (of varying extent, depending on conditions as will be apparent to the skilled person). This will result in a viscosity enhancement or gelation (the effect depending on concentration). The rate at which this occurs can be steered with reference to variable parameters such as pH and concentration, so as to obtain immediate or retarded fibrillary aggregation. Particularly if a retarded effect is desired, it will be advantageous to add the pre-fibril peptide composition in an encapsulated form. This can have the advantage of further retarding the effect from fibrillary aggregation.

Retarded fibril formation provides a particular advantage in production, as the product can be maintained as a low-viscous mass during processing steps, such as pumping, in which a low viscosity can be beneficial.

The pre-fibril peptide composition has a great advantage in that it does not itself have a substantial influence on the texture of foods and drinks. This enables making a solid or liquid food product that has a built-in effect of satisfying the stomach (satiation). Thus, when consumed by a person, the peptide composition will not disturb mouthfeel, as it will remain intact until it arrives in the gastric juice. Due to the pH thereof, and the benefit of elevated (body) temperature, fibrillary aggregation will occur almost instantaneously. Due to the gelation occurring *in situ* there, the person consuming the food product containing the pre-fibril composition of the invention, will experience satiety, i.e. the impression of a relatively larger meal than actually consumed. This can also have benefit for animal diet foods, e.g. for companion animals. In view of peptide taste, it will be preferred to employ the pre-fibril composition in taste-masked or encapsulated form, particularly if relatively small hydrophobic peptides are substantially present. In another preferred embodiment, in which pre-fibril composition are chosen that are enriched in

respect of the aforementioned relatively large peptides, an advantage is a decreased need for taste-masking measures.

Techniques for taste-masking and/or for the encapsulation of peptides are known to the skilled person, and do not require elucidation here.

The invention also pertains to fibrils of a proteinaceous material based on a β -lactoglobulin-containing whey protein preparation obtainable by a process as substantially described hereinbefore. I.e. the process of two steps, comprising first subjecting the protein to hydrolysis so as to form peptides, and then allowing fibril formation to occur at acidic pH. The resulting products, by tailoring the peptide composition, are distinguished from a process in which the β -lactoglobulin-containing whey protein preparation is subjected to a concerted process of hydrolysis and fibrillary aggregation.

The invention encompasses the use of the aforementioned pre-fibril compositions, as well as the fibrils obtainable in accordance with the invention, in food products, particularly in acidic dairy products such as yoghurt or cheese. This use serves the aforementioned purposes, such as providing structuring properties. The invention also encompasses the resulting food products.

In the invention combinations of the various fibrils can be made. Further, combinations can be made with peptides obtainable from lysozyme, which are also fibril-forming.

The invention will be further illustrated hereinafter with reference to the following, non-limiting examples, that include a description of the Figures.

Example 1

The pH of a 3% protein solution of bovine β -lactoglobulin was set to 2 by adding a concentrated HCl solution and heated for 20 hours at 85°C in a

shearing device at a constant shear rate of 323 s⁻¹. During this heat treatment fibrillar aggregates were formed. The heated sample was diluted to a protein concentration of 0.8 g/l. Fibrils and non-aggregated protein material of the sample were separated using centrifugal filters (MWCO 100,000). The retentate contained fibrillar aggregates, as was shown by Thioflavin T fluorescence measurements, high-performance size-exclusion-chromatography under non-dissociating condition, and transmission electron microscopy. The filtrate did not contain fibrils.

The retentate was washed and centrifuged twice with a pH 2 HCl solution to remove non-aggregated proteinaceous material left in the retentate. The proportion of proteinaceous material present in the fibrils in the heated β -lactoglobulin solution was approximately 28 wt%.

Analysis of the retentate with high-performance size-exclusion-chromatography under fibril dissociating conditions showed that in the total heated sample, retentate and filtrate, no peak was visible at the position of unheated β -lactoglobulin, and all material eluted later than unheated β -lactoglobulin, indicating that the fibrils are not composed of intact β -lactoglobulin molecules, but peptides derived from the acid hydrolysis that takes place during heating at pH 2.

Molecular masses of the peptides present in the heated sample, retentate and filtrate were characterized using MALDI-TOF mass-spectrometry. The peptides had molecular masses between 2,000 and 8,000 Da, which means that the fibrils are composed of peptide fragments. The majority of the peptide fragments (both aggregated and non-aggregated) were a result of cleavage of the peptide bonds before or after aspartic acid. Four peptide fragments were present in the retentate and the total heated sample and not present in the filtrate, viz. [f1-32], [f1-33], [f1-52] and [f1-53]. The peptide fragment

dominantly present in the fibrils was [f12-33], i.e., IQKVAGTWYSLAMAASDISLL. This peptide was also present in the filtrate.

Example 2

A solution of 2 wt% β -lactoglobulin in 50 mM Tris-HCl and 2 mM zinc acetate, pH 8, was incubated at 37°C with AspN endoproteinase (P8104S, New England Biolabs), which cleaves peptide bonds N-terminal to aspartic acid residues. After hydrolysis ~20% of intact β -lactoglobulin was present, while the rest of the protein was hydrolyzed into peptides of different sizes. The hydrolyzed protein solution was then acidified to pH 2. As a result, the viscosity increased.

Figure 1 shows a transmission electron microscopy image of the β -lactoglobulin solution after enzymatic hydrolysis and incubation at pH 2. Fibrillar aggregates with a length of ~1 μ m can be observed in this picture, which shows that the enzymatic hydrolysis is an alternative route to obtain fibrillar aggregates of β -lactoglobulin.

Example 3

Fibrils of protein like β -lactoglobulin and soy glycinin can be prepared by heating the protein at pH 2. The peptides present after heating at pH 2 were a result of hydrolysis of the bonds between an aspartic acid residue and any other amino acid residue. Fibrils of soy glycinin are also predominantly composed of peptides. An isolate of soy glycinin was prepared from soy bean meal using isoelectric precipitation at pH 6.4. Fibrils of soy glycinin were prepared by heating (85 °C, 20 h) and shearing (shear rate of 323 s⁻¹) a 2 wt%

soy glycinin solution at pH 2. After this treatment, fibrils and non-aggregated proteins were separated from each other using centrifugal filter tubes (molecular weight cut off of 100 kDa). The non-separated fraction, the fibril fraction, the non-aggregated fraction and unheated soy glycinin were analyzed using HP-SEC (high performance size-exclusion-chromatography). Fibril dissociating conditions were used, which means that the samples were dissolved in a buffer containing 8 M guanidine chloride and 0.1M 1,4-dithiothreitol (pH 8). The HP-SEC elution profiles of the different samples is shown in Figure 2.

Figure 2 depicts HP-SEC (fibril dissociating conditions) elution profiles of (a) unheated soy glycinin, (b) total heated sample, (c) fibril fraction, and (d) non-aggregated protein material. Fibrils were dissociated using 8 M guanidine chloride and 0.1 M DTT (pH 8). The increase in UV signal of the elution profile after 11.5 ml (indicated by the dotted line) is due to the elution of guanidine chloride.

The heated material eluted later than the unheated soy glycinin solution, which shows that hydrolysis took place during the heat treatment at pH 2. Thus, peptides were present after the heat treatment. Most material present in the fibril fraction also eluted later than the unheated soyglycinin. This shows that soy glycinin fibrils are predominantly composed of peptides.

Example 4

Fibrils were obtained from patatin by heating and stirring a 2 wt% protein solution for 24 h at 70 °C and pH 2. Figure 3 shows a TEM picture of the fibrils obtained from patatin. These fibrils were shorter (~500 nm) and more flexible than fibrils formed from soy protein or β -lactoglobulin.

Example 5

The conditions described for Example 1 were used with the exception that 8 M urea was added to the starting mixture.

The presence of urea in the mixture affects the formation of fibrils, but does not affect the hydrolysis of the of the bovine β -lactoglobulin. Urea counteract the formation of hydrogen bonds and hydrophobic interactions which interactions are believed to be the initial force for fibril formation.

After 20 hours the solution was cooled to room temperature, and the pH was increased from pH 2 to pH 7 by drop-wise addition of NaOH (aq). The urea was removed by chromatography (anion exchange). Thioflavin T fluorescence measurement and transmission electron microscopy was used to confirm the absence of fibrils

Claims

1. A peptide pre-fibril composition obtainable by the hydrolysis of a protein selected from the group consisting of β -lactoglobulin-containing whey protein preparation, glycinin-containing soy bean protein preparation, patatin, and mixtures thereof, wherein the hydrolysis is conducted under acidic conditions at a temperature higher than 20°C, and terminating the hydrolysis by increasing the pH to neutral.
2. A peptide pre-fibril composition according to claim 1, wherein the hydrolysis is conducted at a pH of 0.5-4, preferably 0.5-3.
3. A peptide pre-fibril composition according to claim 1 or 2, wherein the hydrolysis is conducted at a temperature of 80-120°C..
4. A peptide pre-fibril composition according to any one of the preceding claims, wherein the protein is β -lactoglobulin.
5. A peptide pre-fibril composition according to claim 4, wherein the dominant peptide in the proteinaceous material is peptide
IQKVAGTWYSLAMAASDISLL.
6. A method of making a peptide pre-fibril composition according to any one of the claims 1-5, comprising subjecting a protein selected from the group consisting of β -lactoglobulin-containing whey protein preparation, glycinin-containing soy bean protein preparation, patatin, and mixtures thereof to hydrolysis conditions by providing a solution of the protein in an aqueous acidic solvent, heating the solution under fibril-inhibiting conditions, and terminating the hydrolysis conditions.
7. A method of making a peptide pre-fibril composition according to any one of the claims 1-5, comprising subjecting the protein to enzymatic hydrolysis.
8. A method according to claim 7, wherein the enzymes are selected such as to obtain cleavage in majority before or after aspartic acid.

9. A method of making a peptide pre-fibril composition according to any one of the claims 1-5, comprising providing one or more micro-organisms capable of forming the appropriate peptides, preferably selected from the group consisting of BACILLUS_WEIHENSTEPHANENSIS, BIFIDOBACTERIUM_ADOLESCENTIS, BIFIDOBACTERIUM_LONGUM, BIFIDOBACTERIUM_LONGUM, BREVIBACTERIUM_LINENS, LACTOBACILLUS_ACIDOPHILUS, LACTOBACILLUS_BREVIS, LACTOBACILLUS_CASEI, LACTOBACILLUS_DELBRUECKII_SUBSP_BULGARICUS, LACTOBACILLUS_GASSERI, LACTOBACILLUS_JOHNSONII, LACTOBACILLUS_PLANTARUM, LACTOBACILLUS_REUTERI, LACTOBACILLUS_SAKEI, LACTOBACILLUS_SALIVARIUS, LACTOCOCCUS_LACTIS_CREMORIS, LACTOCOCCUS_LACTIS_LACTIS, LEUCONOSTOC_MESENTEROIDES, OENOCOCCUS_OENI, and PEDIOCOCCUS_PENTOSACEUS, STREPTOCOCCUS_THERMOPHILUS, allowing the micro-organisms to form these peptides, and harvesting the peptides.

10. A method of making a proteinaceous fibril composition, comprising making a peptide pre-fibril composition by a method according to any one of the claims 6 to 9, and in a next step subjecting the pre-fibril composition to an acidic pH at elevated temperature for a sufficient duration to allow fibrillary aggregation to start.

11. The use of a peptide pre-fibril composition according to any one of the claims 1-5 as an additive in a food or non-food product.

12. A use according to claim 11, wherein the food product is a human or animal diet-food or diet-drink for weight-control, and wherein the pre-fibril composition is capable of fibrillary aggregation in gastric juice.

13. A use according to claim 11, wherein the food product is a human or animal food or drink, and wherein the pre-fibril composition is prevented from completing fibrillary aggregation in gastric juice, preferably by comprising one

or more substances that counteract hydrogen bond and hydrophobic interactions of the peptides.

14. A use according to claim 11, wherein the food product is an acidic food or drink such as a yoghurt or cheese, and wherein the pre-fibril composition is allowed to form fibrils after production.

15. Fibrils of a proteinaceous material based on a protein preparation selected from the group consisting of β -lactoglobulin-containing whey protein preparation, glycinin-containing soy bean protein preparation, patatin, and mixtures thereof, obtainable by a process comprising first subjecting the protein to hydrolysis so as to form peptides, and then allowing fibril formation to occur at acidic pH.

16. The use of fibrils according to claim 15, in a food product such as yoghurt or cheese.

17. A food product, such as yoghurt or cheese, comprising a peptide pre-fibril composition according to any one of the claims 1-5.

18. A food product, such as yoghurt or cheese, comprising fibrils according to claims 15.

Figure 1




Figure 2




Figure 3

